TY - JOUR
T1 - Homologous tropomyosins from vertebrate and invertebrate
T2 - Recombinant calibrator proteins in functional biological assays for tropomyosin allergenicity assessment of novel animal foods
AU - Klueber, Julia
AU - Costa, Joana
AU - Randow, Stefanie
AU - Codreanu-Morel, Françoise
AU - Verhoeckx, Kitty
AU - Bindslev-Jensen, Carsten
AU - Ollert, Markus
AU - Hoffmann-Sommergruber, Karin
AU - Morisset, Martine
AU - Holzhauser, Thomas
AU - Kuehn, Annette
N1 - Funding Information:
Funding information This work was supported by the Ministry of Research, Luxembourg (JK, AK, MO), the PRIDE program grant (PRIDE/11012546/NEXTIMMUNE) by the Fonds National de la Recherche (FNR), Luxembourg (JK, AK, MO) and the COST Action FA1402 ImpARAS (JK, TH, JC, KV, KHS, AK). A supportive grant for laboratory consumables was received by Laboratoires R?unis, Luxembourg (JK, AK, MO). We thank T Scheuermann, D Revets, K Benkirane and T Graf for their great technical support.
Publisher Copyright:
© 2019 The Authors. Clinical & Experimental Allergy published by John Wiley & Sons Ltd.
PY - 2020/1/1
Y1 - 2020/1/1
N2 - Background: Novel foods may provide new protein sources for a growing world population but entail risks of unexpected food-allergic reactions. No guidance on allergenicity assessment of novel foods exists, while for genetically modified (GM) crops it includes comparison of sequence identity with known allergens, digestibility tests and IgE serum screening. Objective: As a proof of concept, to evaluate non-/allergenic tropomyosins (TMs) regarding their potential as new calibrator proteins in functional biological in vitro assays for the semi-quantitative allergy risk assessment of novel TM-containing animal foods with mealworm TM as an example. Methods: Purified TMs (shrimp, Penaeus monodon; chicken Gallus gallus; E coli overexpression) were compared by protein sequencing, circular dichroism analysis and in vitro digestion. IgE binding was quantified using shrimp-allergic patients' sera (ELISA). Biological activities were investigated (skin testing; titrated basophil activation tests, BAT), compared to titrated biological mediator release using humanized rat basophil leukaemia (RBL) cells. Results: Shrimp and chicken TMs showed high sequence homology, both alpha-helical structures and thermal stability. Shrimp TM was stable during in vitro gastric digestion, chicken TM degraded quickly. Both TMs bound specific IgE from shrimp-allergic patients (significantly higher for shrimp TM), whereas skin reactivity was mostly positive with only shrimp TM. BAT and RBL cell assays were positive with shrimp and chicken TM, although at up to 100- to 1000-times lower allergen concentrations for shrimp than chicken TM. In RBL cell assays using both TM as calibrators, an activation of effector cells by mealworm TM similar to that by shrimp TM confirmed the already reported high allergenic potency of mealworm TM as a novel protein source. Conclusions & clinical relevance: According to current GM crops' allergenicity assessment, non-allergenic chicken TM could falsely be considered an allergen on a weight-of-evidence approach. However, calibrating allergenic potency in functional BAT and RBL cell assays with clinically validated TMs allowed for semi-quantitative discrimination of novel food protein's allergenicity. With TM calibration as a proof of concept, similar systems of homologous protein might be developed to scale on an axis of allergenicity.
AB - Background: Novel foods may provide new protein sources for a growing world population but entail risks of unexpected food-allergic reactions. No guidance on allergenicity assessment of novel foods exists, while for genetically modified (GM) crops it includes comparison of sequence identity with known allergens, digestibility tests and IgE serum screening. Objective: As a proof of concept, to evaluate non-/allergenic tropomyosins (TMs) regarding their potential as new calibrator proteins in functional biological in vitro assays for the semi-quantitative allergy risk assessment of novel TM-containing animal foods with mealworm TM as an example. Methods: Purified TMs (shrimp, Penaeus monodon; chicken Gallus gallus; E coli overexpression) were compared by protein sequencing, circular dichroism analysis and in vitro digestion. IgE binding was quantified using shrimp-allergic patients' sera (ELISA). Biological activities were investigated (skin testing; titrated basophil activation tests, BAT), compared to titrated biological mediator release using humanized rat basophil leukaemia (RBL) cells. Results: Shrimp and chicken TMs showed high sequence homology, both alpha-helical structures and thermal stability. Shrimp TM was stable during in vitro gastric digestion, chicken TM degraded quickly. Both TMs bound specific IgE from shrimp-allergic patients (significantly higher for shrimp TM), whereas skin reactivity was mostly positive with only shrimp TM. BAT and RBL cell assays were positive with shrimp and chicken TM, although at up to 100- to 1000-times lower allergen concentrations for shrimp than chicken TM. In RBL cell assays using both TM as calibrators, an activation of effector cells by mealworm TM similar to that by shrimp TM confirmed the already reported high allergenic potency of mealworm TM as a novel protein source. Conclusions & clinical relevance: According to current GM crops' allergenicity assessment, non-allergenic chicken TM could falsely be considered an allergen on a weight-of-evidence approach. However, calibrating allergenic potency in functional BAT and RBL cell assays with clinically validated TMs allowed for semi-quantitative discrimination of novel food protein's allergenicity. With TM calibration as a proof of concept, similar systems of homologous protein might be developed to scale on an axis of allergenicity.
KW - allergenicity assessment
KW - basophil activation test
KW - chicken
KW - rat basophil leukaemia cell mediator release
KW - shrimp
KW - shrimp allergy
KW - tropomyosin
UR - http://www.scopus.com/inward/record.url?scp=85074033405&partnerID=8YFLogxK
UR - https://pubmed.ncbi.nlm.nih.gov/31541579
U2 - 10.1111/cea.13503
DO - 10.1111/cea.13503
M3 - Article
C2 - 31541579
AN - SCOPUS:85074033405
SN - 0954-7894
VL - 50
SP - 105
EP - 116
JO - Clinical and Experimental Allergy
JF - Clinical and Experimental Allergy
IS - 1
ER -